Le Lézard
Classified in: Science and technology
Subjects: TDS, FVT

TE Connectivity to present at Baird's 2020 Global Industrial Conference


SCHAFFHAUSEN, Switzerland, Oct. 29, 2020 /PRNewswire/ -- TE Connectivity Ltd. (NYSE: TEL) announced today that Chief Executive Officer Terrence Curtin will present virtually at Baird's 2020 Global Industrial Conference on Tuesday, Nov. 10, 2020 at 7:55 a.m. ET. The webcast will be live on the company's investor website at investors.te.com. A replay of the presentation will be archived and available at the same location.

ABOUT TE CONNECTIVITY 
TE Connectivity is a $12 billion global industrial technology leader creating a safer, sustainable, productive and connected future. Our broad range of connectivity and sensor solutions, proven in the harshest environments, enable advancements in transportation, industrial applications, medical technology, energy, data communications and the home. With approximately 80,000 employees, including more than 7,500 engineers, working alongside customers in approximately 140 countries, TE ensures that EVERY CONNECTION COUNTS. Learn more at www.te.com and on LinkedIn, Facebook, WeChat and Twitter.

 

SOURCE TE Connectivity Ltd.


These press releases may also interest you

at 18:05
GlycoMimetics' product candidate uproleselan ? when added to a combination therapy of venetoclax and a hypomethylating agent (HMA) ? was shown today in an oral presentation to break chemoresistance by dramatically and significantly reducing tumor...

at 18:00
Quanta X Technology, the parent company of QuantaDose, CEO Katie Webb suggests, "Anyone in Santa's shoes gifting a UVC device to a friend or family member needs to make sure the UV-C device is real, and they also need to understand the potential...

at 17:00
63% response rate in patients treated with the highest reported dose Among all patients responding to treatment, 95% experienced a very good partial response or better; among responding patients with ?6 months of follow-up, 83% have ongoing responses...

at 16:30
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from an ongoing Phase 1 first-in-human dose escalation study (NCT03145181) of teclistamab (JNJ-64007957) for the treatment of relapsed or refractory multiple...

at 15:30
Gracell Biotechnologies Inc. ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced an interim readout to evaluate the...

at 15:05
bluebird bio, Inc. today presented updated long-term efficacy and safety results reflecting up to six years of data for betibeglogene autotemcel gene therapy (beti-cel; formerly LentiGlobintm for ?-thalassemia) in patients with transfusion-dependent...



News published on 29 october 2020 at 09:34 and distributed by: